Table 3 PARP1 genotypes and overall survival.

From: Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy

Variables

5 y OS(%)

Crude

Adjusted

HR (95% CI)

P

HR (95% CI)

P

rs1136410

TT

87.3

1(Ref)

 

1(Ref)

 

TC

90.5

0.578(0.239–1.395)

0.222

0.818(0.334–2.008)

0.662

CC

77.1

1.382(0.555–3.439)

0.487

1.572(0.607–4.073)

0.352

rs11801168

TT

85.7

1(Ref)

 

1(Ref)

 

TC

91.5

0.344(0.066–1.788)

0.204

0.663 (0.123–3.570)

0.632

CC

85.3

0.486(0.113–2.090)

0.332

0.990(0.214–4.577)

0.990

Rs12568297

GG

85.5

1(Ref)

 

1(Ref)

 

GC

95.0

0.470(0.111–1.989)

0.305

0.451(0.105–1.942)

0.285

CC

80.0

2.823(0.658–12.110)

0.162

1.678(0.343–8.214)

0.523

Rs6664761

TT

85.2

1(Ref)

 

1(Ref)

 

TC

90.4

0.772(0.205–2.915)

0.703

1.079(0.279–4.178)

0.912

CC

84.4

1.522(0.446–5.196)

0.503

1.974(0.563–6.919)

0.288

Rs7531668

TT

84.3

1(Ref)

 

1(Ref)

 

TA

91.4

0.486 (0.183–1.289)

0.147

0.483(0.180–1.292)

0.147

AA

90.4

0.499(0.117–2.130)

0.348

0.376(0.087–1.628)

0.191

  1. Abbreviations: DFS, disease free survival; OS, overall survival; HR, hazard ratios; CI, confidence interval; Ref, reference.